Zobrazeno 1 - 10
of 299
pro vyhledávání: '"Philip Bonomi"'
Autor:
Mary Jo Fidler, Cristina L. Fhied, Joanna Roder, Sanjib Basu, Selina Sayidine, Ibtihaj Fughhi, Mark Pool, Marta Batus, Philip Bonomi, Jeffrey A. Borgia
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used to predict differential benefit from erlotinib versus chemotherapy in previously tr
Externí odkaz:
https://doaj.org/article/50ebd1b8392c48aa9f668f55a3ffc1c6
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 4 (2012)
The insulin-like growth factor (IGF) pathway is a complex pathway involving interactions between membrane-bound receptors, ligands, binding proteins, downstream effectors, and other receptor tyrosine kinase signaling cascades. The IGF pathway has bee
Externí odkaz:
https://doaj.org/article/c2d22aefd727478fb336df23ca9f9d5e
Autor:
Richard A. Miller, Stephen B. Willingham, Long Kwei, Ian McCaffery, Jessica Hsieh, Po Y. Ho, Brian Munneke, Rachel A. Goodwin, Daniel J. Renouf, Lyudmyla Berim, Jonathan W. Goldman, Philip Bonomi, Leonel Hernandez-Aya, Joshua D. Brody, Ginna Laport, Jason J. Luke, Daruka Mahadevan, Leisha A. Emens, Ben Markman, Matthew J. Riese, Amy M. Weise, Shivaani Kummar, Brian I. Rini, Dale R. Shepard, Matthew D. Hellmann, Brett G.M. Hughes, Saby George, Toni K. Choueiri, Rebecca S. Heist, Mario Sznol, John D. Powderly, Andrew Hotson, Lawrence Fong
Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinical trial wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1a4eb0824258054770e529fd0c7d5f1
https://doi.org/10.1158/2159-8290.c.6547840.v1
https://doi.org/10.1158/2159-8290.c.6547840.v1
Autor:
Richard A. Miller, Stephen B. Willingham, Long Kwei, Ian McCaffery, Jessica Hsieh, Po Y. Ho, Brian Munneke, Rachel A. Goodwin, Daniel J. Renouf, Lyudmyla Berim, Jonathan W. Goldman, Philip Bonomi, Leonel Hernandez-Aya, Joshua D. Brody, Ginna Laport, Jason J. Luke, Daruka Mahadevan, Leisha A. Emens, Ben Markman, Matthew J. Riese, Amy M. Weise, Shivaani Kummar, Brian I. Rini, Dale R. Shepard, Matthew D. Hellmann, Brett G.M. Hughes, Saby George, Toni K. Choueiri, Rebecca S. Heist, Mario Sznol, John D. Powderly, Andrew Hotson, Lawrence Fong
Supplemental Appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3071ba39347d3fcb4739fac2eed11e81
https://doi.org/10.1158/2159-8290.22535371.v1
https://doi.org/10.1158/2159-8290.22535371.v1
Autor:
Thomas E. Stinchcombe, Michael W. Lu, Lisa H. Lam, Sanne de Haas, Christoph Meyenberg, Marcello Tiseo, Achim Rittmeyer, Pilar Garrido, Javier De Castro Carpeno, Dolores Isla, Christina S. Baik, Dariusz M. Kowalski, Augusto Villegas, Philip Bonomi, Lukas Bubendorf, Rolf Stahel, Solange Peters
Supplementary appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4121109b492808668e044a0750d98691
https://doi.org/10.1158/1078-0432.22472889.v1
https://doi.org/10.1158/1078-0432.22472889.v1
Autor:
Thomas E. Stinchcombe, Michael W. Lu, Lisa H. Lam, Sanne de Haas, Christoph Meyenberg, Marcello Tiseo, Achim Rittmeyer, Pilar Garrido, Javier De Castro Carpeno, Dolores Isla, Christina S. Baik, Dariusz M. Kowalski, Augusto Villegas, Philip Bonomi, Lukas Bubendorf, Rolf Stahel, Solange Peters
Purpose:HER2-targeted therapy is not standard of care for HER2-positive non–small cell lung cancer (NSCLC). This phase II study investigated efficacy and safety of the HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28077f4aade9ce86a46fc9d4a1707298
https://doi.org/10.1158/1078-0432.c.6528357
https://doi.org/10.1158/1078-0432.c.6528357
Autor:
Geoffrey I. Shapiro, Wei Guo, Florentina Teofilovici, Kwok-Kin Wong, Suresh Ramalingam, Mark Huberman, Harry Harper, Timothy Webb, Chandra P. Belani, Alan Sandler, Lin-Chi Chen, Julie Brahmer, Philip Bonomi, Lecia V. Sequist, Howard West, Ravi Salgia, Eugene Paschold, Leora Horn, Vojo Vukovic, Marianna Koczywas, Iman El-Hariry, Jonathan Goldman, Mark A. Socinski
PDF file - 91K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34459da61b5b15889b0d3dcf34581138
https://doi.org/10.1158/1078-0432.22452692.v1
https://doi.org/10.1158/1078-0432.22452692.v1
Autor:
Geoffrey I. Shapiro, Wei Guo, Florentina Teofilovici, Kwok-Kin Wong, Suresh Ramalingam, Mark Huberman, Harry Harper, Timothy Webb, Chandra P. Belani, Alan Sandler, Lin-Chi Chen, Julie Brahmer, Philip Bonomi, Lecia V. Sequist, Howard West, Ravi Salgia, Eugene Paschold, Leora Horn, Vojo Vukovic, Marianna Koczywas, Iman El-Hariry, Jonathan Goldman, Mark A. Socinski
Purpose: Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), a chaperone protein critical to tumor growth and proliferation. In this phase II study, we evaluated the activity and tolerability of ganetespib in previously treated pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5af70f1f0f27b1a60448b6e5137abbd6
https://doi.org/10.1158/1078-0432.c.6522557.v1
https://doi.org/10.1158/1078-0432.c.6522557.v1
Autor:
Aamir Ahmed, Jason Kramer, Mohamad Hemu, Andres Palomo, Parva Bhatt, Kyaw Zaw Hein, Tochukwu M. Okwuosa, Megan Randall, Ibtihaj Fughhi, Philip Bonomi, Louis Fogg, Talal Mourad, Caleb Chiang
Publikováno v:
J Thorac Dis
BackgroundSinus tachycardia in cancer reflects significant multi-system organ stressor and disease, with sparse literature describing its clinical significance. We assessed cardiovascular (CV) and mortality prognostic implications of sinus tachycardi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e4b42d55377368e38a6214b08688744
https://doi.org/10.21203/rs.3.rs-150770/v1
https://doi.org/10.21203/rs.3.rs-150770/v1
Autor:
Revathi Kollipara, Jeffrey A. Borgia, Philip Bonomi, Marta Batus, Imad Tarhoni, Mary J. Fidler, Connor Wakefield
Publikováno v:
Journal of immunological methods. 490
Durable tumor regressions are observed in a subset of advanced-stage non-small cell lung cancer (NSCLC) patients receiving PD-1/-L1 targeted immune checkpoint inhibitors (or 'immunotherapy') alone or in combination with chemotherapy. However, the maj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12e1aeba7c5bc0f005f8b630b28114a4
https://pubmed.ncbi.nlm.nih.gov/33434603
https://pubmed.ncbi.nlm.nih.gov/33434603